Wordt geladen...
Low-dose Naltrexone for the treatment of sarcoidosis
Systemic therapy is administered to 50% of patients and the need for long-term use of therapy is quite variable (1,2). Prednisone is often administered for many months with risk for multiple side effects, immunomodulators as steroid sparing agents have a delayed onset of action and have risks for in...
Bewaard in:
| Gepubliceerd in: | Sarcoidosis Vasc Diffuse Lung Dis |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Mattioli 1885
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7170144/ https://ncbi.nlm.nih.gov/pubmed/32476841 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.36141/svdld.v34i2.5303 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|